Complete Radiologic Response in Metastatic Castration-Resistant Prostate Cancer Treated with Cabazitaxel
Authors
Abstract:
This article doesn't have abstract
similar resources
Prognostic factors in men with metastatic castration-resistant prostate cancer treated with cabazitaxel
Background Treatment selection for men with metastatic castration-resistant prostate cancer (mCRPC) has become increasingly challenging with the introduction of novel therapies at earlier disease stages. The purpose of this study was to identify prognostic factors for overall survival (OS) and PSA response in patients with mCRPC treated with cabazitaxel. Results 224 mCRPC patients were includ...
full textProlonged therapy with cabazitaxel in an octogenarian with metastatic castration-resistant prostate cancer.
Case Report A 73-year-old man with a past medical history of diabetes and gout was noted by his urologist to have an abnormal digital rectal examination in April 1997. Core biopsies of the prostate were performed, revealing Gleason 7 (4 3) disease comprising roughly 50% of 6 pecimens. The patient was treated with brachytherapy, and the paient’s prostatic-specific antigen (PSA) level declined to...
full textSustained complete response to CTLA-4 blockade in a patient with metastatic, castration-resistant prostate cancer.
We present the case of a man with metastatic, castration-resistant prostate cancer, who had a complete prostate-specific antigen (PSA) response after 2½ doses of ipilimumab. His treatment course was complicated by diarrhea and autoimmune hepatitis, both of which resolved within 4 months. Sera and biopsy specimens were accessed, and sera from pretreatment and day 113 were analyzed. Augmented ant...
full textCabazitaxel in the Management of Metastatic Castration-resistant Prostate Cancer Progressing After Docetaxel-based Chemotherapy
Docetaxel is the guideline-recommended first-line chemotherapy in men with castration-resistant prostate cancer (CRPC). Despite its proven survival benefit, however, all patients will progress after a mean interval of six to eight months. Recently, the FDA approved cabazitaxel and abiraterone acetate as effective second-line treatment options in this clinical scenario. By comparison with mitoxa...
full textCabazitaxel in the treatment of metastatic castration-resistant prostate cancer: patient selection and special considerations
Cabazitaxel is an effective chemotherapeutic agent used in the treatment of metastatic castration-resistant prostate cancer (mCRPC) refractory to docetaxel. With the advent of new antiandrogen therapies, immune-based treatments, and radioactive-targeted therapy, there are now multiple effective and approved agents for this disease state. The optimal sequencing of these agents is unclear as ther...
full textMy Resources
Journal title
volume 40 issue 3
pages 294- 296
publication date 2015-05-01
By following a journal you will be notified via email when a new issue of this journal is published.
Hosted on Doprax cloud platform doprax.com
copyright © 2015-2023